Skip to main content

Table 5 Univariate/multivariate analyses of factors associated with prognosis in the p-DCS group

From: Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study

  Univariate analysis Multivariate analysis
Variable No. of patients HR 95% CI P value HR 95% CI P value
Age (years) ≥70 15 1.470 (0.607–3.560) 0.393    
<70 24
Gender Male 32 0.409 (0.156–1.075) 0.070 0.281 (0.093–0.846) 0.024
Female 7
ECOG performance status ≥1 2 0.894 (0.119–6.698) 0.913    
0 37
Borrmann macroscopic type Non-type 4 38 0.452 (0.059–3.439) 0.443    
Type 4 1
Differentiation Diffuse 18 0.758 (0.310–1.854) 0.543    
Intestinal 21
PAN metastasis (+) 16 1.869 (0.539–4.854) 0.201    
(−) 23
Hepatic metastasis (+) 9 2.508 (0.993–6.333) 0.052 1.718 (0.530–5.570) 0.367
(−) 30
RECIST SD, PD 10 1.769 (0.705–4.439) 0.225    
CR, PR 29
Histological evaluation 0, 1a, 1b 17 2.84 (1.152–7.000) 0.023 1.938 (0.612–6.129) 0.260
2, 3 22
CD42b expression ≥10% 24 3.644 (1.213–10.95) 0.021 4.406 (1.325–14.65) 0.016
<10% 15
Podoplanin expression (+) 28 1.411 (0.512–3.889) 0.505    
(−) 11
SNAIL expression (+) 30 1.736 (0.664–4.539) 0.261    
(−) 9
FOXP3 expression (+) 7 1.272 (0.369–4.386) 0.703    
(−) 32
  1. CI confidence interval, CR complete response, ECOG Eastern Cooperative Oncology Group, FOXP3 forkhead box P3, HR hazard ratio, PD progressive disease, PR partial response, RECIST Response Evaluation Criteria in Solid Tumors, SD stable diseases
\